Slowave

Slowave operates at the intersection of digital health, medical devices, wellness, and neurotechnology. Its stated focus is EEG-based sleep monitoring and neurological diagnostics, with a wearable patch intended to reduce the burden of conventional sleep testing. The company describes a proprietary PIA (Phase Information Analysis) algorithm that analyzes phase relationships and information flow across brain networks, rather than relying only on conventional power-spectrum analysis. Its Slowave1.0 Wellness system combines EEG and PPG sensing for home sleep monitoring and is explicitly positioned as a wellness product, not a medical device. The company also describes a separate compact EEG solution for sleep diagnosis under medical supervision. Slowave’s profile therefore supports a description of its category and technical approach, but not a confident ranking against named rivals. The company lists GMP and CB certifications and Korean Class II medical-device certification; these credentials provide context for its product development, not proof of comparative advantage.

Slowave was founded in 2022 and has a recorded employee-size band of 1–10, indicating a small operating footprint. Its financing history comprises a seed round dated Jul 7, 2023, a TIPS Program grant dated Nov 1, 2023, and a further seed round led by Korea Technology Finance Corporation on Nov 1, 2025. Product development centers on wearable EEG: the company describes a lightweight patch, a scalable channel architecture, PIA brain-signal analysis, and the Slowave1.0 Wellness home sleep-monitoring system. Its profile also describes a medically supervised sleep-diagnosis solution. A patent-related timeline item is dated Dec 12, 2022. Overall, the known trajectory is an early-stage company moving from initial seed financing and grant support to another seed round while developing EEG-based products; further progress remains difficult to quantify from the available public information.